ReviewCancer cell international2020
The yin and yang functions of extracellular ATP and adenosine in tumor immunity.
Review in Cancer cell international, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 61 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
61 citing papers in PubMed, 88 citations in OpenAlex.
- Clitocine suppresses TNBC progression by boosting CCRL2 to block survival signals and neutrophil-driven inflammation.Journal of biological engineering · 2026Article
- Single DNA hairpin nanowire based on self-hybridization chain reaction for sensitive ATP detection.Science and technology of advanced materials · 2026Article
- Ferroptosis Enhances T Lymphocyte Infiltration into Glioblastoma Spheroids.Antioxidants (Basel, Switzerland) · 2025Article
- Advances in cold atmospheric plasma therapy for cancer.Bioactive materials · 2025Review
- Immunometabolism shapes chronic Staphylococcus aureus infection: insights from biofilm infection models.Current opinion in microbiology · 2025Review
- P2 purinergic receptors regulate the progression of colorectal cancer.Purinergic signalling · 2025Review
- Role of macrophage ATP metabolism disorder in SiOPurinergic signalling · 2025Review
- Purinergic pathways and their clinical use in the treatment of acute myeloid leukemia.Purinergic signalling · 2025Review
- Clostridioides difficile meets the adenosine system: the art of manipulating host homeostasis.Journal of biomedical science · 2025Review
- Therapeutic potential of tumor-associated neutrophils: dual role and phenotypic plasticity.Signal transduction and targeted therapy · 2025Review
- P2 purinergic receptor expression and function in tumor-related immune cells.Purinergic signalling · 2025Review
- Biofilm formation by the host microbiota: a protective shield against immunity and its implication in cancer.Molecular cancer · 2025Review
- Purinergic system in cancer stem cells.Purinergic signalling · 2025Review
- P2X7 receptor in macrophage polarization and its implications in neuroblastoma tumor behavior.Purinergic signalling · 2025Article
- Leveraging adenosine triphosphate for cancer theranostics.Theranostics · 2025Review
- Cd39 and P2rx7-Wnt signaling enhance blast pathogenicity in an experimental model of acute myeloid leukemia.Haematologica · 2025Article
- The Role of Adenosine in Overcoming Resistance in Sarcomas.International journal of molecular sciences · 2024Review
- Integrated transcriptomic analysis reveals dysregulated immune infiltration and pro-inflammatory cytokines in the secretory endometrium of recurrent implantation failure patients.Life medicine · 2024Article
- Chemoproteomics reveals immunogenic and tumor-associated cell surface substrates of ectokinase CK2α.Cell chemical biology · 2024Article
- Mesenchymal Stem/Stromal Cells Derived from Dental Tissues Mediate the Immunoregulation of T Cells through the Purinergic Pathway.International journal of molecular sciences · 2024Article
1 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Extracellular adenosine triphosphate (eATP) and its main metabolite adenosine (ADO) constitute an intrinsic part of immunological network in tumor immunity. The concentrations of eATP and ADO in tumor microenvironment (TME) are controlled by ectonucleotidases, such as CD39 and CD73, the major ecto-enzymes expressed on immune cells, endothelial cells and cancer cells. Once accumulated in TME, eATP boosts antitumor immune responses, while ADO attenuates immunity against tumors. eATP and ADO, like yin and yang, represent two opposite aspects from immune-activating to immune-suppressive signals. Here we reviewed the functions of eATP and ADO in tumor immunity and attempt to block eATP hydrolysis, ADO formation and their contradictory effects in tumor models, allowing the induction of effective anti-tumor immune responses in TME. These attempts documented that therapeutic approaches targeting eATP/ADO metabolism and function may be effective methods in cancer therapy.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.